Access cutting-edge uveal melanoma treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Access uveal melanoma specialists in San Francisco at no cost
This study follows strict safety protocols and ethical guidelines
All study-related uveal melanoma treatment provided free
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2
Sponsor: IDEAYA Biosciences
Check if you qualify for this uveal melanoma clinical trial in San Francisco, CA
If you're searching for uveal melanoma treatment options in San Francisco, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced uveal melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.